Indian Drug Major Partners With US-Based Gilead Sciences To Manufacture Potential COVID-19 Drug Remidesivir

Indian pharmaceuticals major with global presence, Jubilant Life Sciences Limited announced on Tuesday (12 May) that it subsidiary Jubilant Generics Limited has entered into a non-exclusive agreement with United States (US) based Gilead Sciences to register, manufacture and sell its investigational drug Remidesivir for COVID-19 in 127 nations including India, reports Hindustan Times.

The development gains significance as the usage of remidesivir is evolving as a potential therapy for COVID-19. The drug, developed by Gilead Sciences has already received Emergency Use Authorisation (EUA) by the USFDA to treat severe cases of COVID-19. Meanwhile, multiple additional clinical trials are ongoing to generate data on the safety and effectiveness of the drug as a treatment for COVID-19.

Company's chairman Shyam S Bhartia also shared that it plans to produce Remidesivir's active pharmaceutical ingredient (API) in-house to bring in cost effectiveness and to ensure its consistent availability.